Know Cancer

forgot password

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis

Phase 2
12 Years
60 Years
Open (Enrolling)
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis

Thank you

Trial Information

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis

Patients being admitted to the hospital for pain crisis may be eligible for this study. In
addition, patients should be 12-60 years old and have sickle cell types SS or
S-beta-thalassemia. People who take part in the study will be evaluated and then randomly
assigned to receive either GMI-1070 or a placebo by IV, in addition to all other usual
treatments for their pain crisis.

During the hospital stay for pain crisis, GMI-1070 or placebo will be given twice a day, and
patients will be asked about their pain severity (pain score) at the beginning of the study
and every few hours during their hospital stay. Their general health, vital signs, lab
tests, and pain medications will also be checked on a regular basis through the hospital
stay. When a patient is feeling well enough to go home, the study drug (GMI-1070 or
placebo) will be stopped, and the patient may go home. Participants will be asked to come
back to clinic for a check-up a few days after leaving the hospital, and one month after
leaving the hospital.

Inclusion Criteria:

1. 12 to 60 years of age

2. Confirmed diagnosis of sickle cell disease (HbSS or HbS-β0thalassemia)

3. Diagnosis of VOC at the time of enrollment

4. Hospitalized or in process of admission at the time of enrollment

5. Able to receive the first dose of study drug within 24 hours of initial medical
evaluation in the Emergency Department/clinic for VOC;

o Subjects treated as an outpatient within the past 48 hours for the same VOC episode
may be enrolled if dosing is also expected within 24 hours of their second
(admitting) presentation.

6. Documented and observed written informed consent (and assent, where applicable)

Exclusion Criteria:

1. Infection, diagnosed or strongly suspected, as evidenced by one or more of the

- Fever >39°C (102.2°F)

- In the presence of fever ≥38.5°C (101.3°F), 1 of the following:

- Positive findings (suspicious for infection) on diagnostic tests, such as
cerebral spinal fluid [CSF] evaluation, radiographs, or bacterial culture
of normally sterile sites

- Exam findings leading to diagnosed or strongly suspected bone or joint

- Determination by physician that bacterial or serious systemic viral
infection is likely (eg, influenza, mononucleosis)

- Subjects may be included with uncomplicated urinary tract infections
(provided they do not have fever ≥38.5° C [101.3° F] or costo-vertebral
angle [CVA] tenderness), and/or suspected minor viral syndromes (upper
respiratory infection symptoms but no symptoms suggestive of bacterial
infection other than uncomplicated otitis media or uncomplicated
streptococcal pharyngitis)

2. Acute chest syndrome, diagnosed or strongly suspected, as evidenced by a new
infiltrate on chest radiograph, and 1 or more of the following:

- Fever >39° C (102.2° F)

- Hypoxia (confirmed by arterial blood gases [ABG] with paO2 <70 mmHg)

- Chest pain

- Suspicious findings on exam (tachypnea, intercostal retractions, wheezing,
and/or rales)

3. Sickle cell disease (SCD) pain atypical of VOC, including hepatic or splenic
sequestration, cholecystitis, or pneumonia.

4. Acute stroke, acute priapism, severe avascular necrosis of the hip/shoulder when the
presenting pain is only in the affected hip/shoulder

5. Serum creatinine:

- >1.2 mg/dL for subjects 16 to 60 years of age

- >1.0 mg/dL for subjects 12 to 15 years of age

6. Alanine transaminase (ALT/SGPT) >2x upper limit of normal (ULN) (based on clinic
laboratory normal range)

7. Hemoglobin <5 g/dL

8. Platelets <100,000/mm3

9. Recent (within the past 30 days) major surgery, hospitalization for other than VOC,
documented serious bacterial infection requiring antibiotic treatment, or significant

10. Hospitalization for uncomplicated VOC, or treated with parenteral pain medications in
other medical settings such as the emergency department or day hospital for
uncomplicated VOC, within past 14 days.

o Subjects may be included if treated as an outpatient within the past 48 hours for
the same VOC episode.

11. Recent (within the past 90 days) cerebrovascular accident, transient ischemic attack,
or seizure

12. pRBC transfusions in the past 14 days

13. Systemic steroid therapy within 48 hours prior to enrollment or expectation that
therapy may be used during the study (inhaled or topical steroids are allowed)

14. For those on chronic or long-acting opioids, a change in dose in the past 14 days OR
pain requiring medical attention in the past 14 days (change in opioid medication for
acute pain in the past 48 hours and directly related to this VOC admission is

15. Greater than 5 episodes of hospitalization for VOC in the past 6 months (180 days)

16. Medical or psychiatric condition that, in the opinion of the investigator, may pose a
risk to the subject for participation or interfere with the conduct or results of the

17. Currently receiving, or has received within the previous 4 weeks, any other
investigational agent

18. Previous administration of GMI-1070

19. Expectation that the subject will not be able to be followed for the duration of the

20. Pregnant or lactating female; or female of childbearing potential or male unable or
unwilling to comply with birth control methods or abstinence during the course of the

21. Active use of illicit drugs and/or alcohol dependence, as determined by the

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Reduction in time to resolution of vaso-occlusive crisis

Outcome Description:

Including pain score, feeling ready to leave the hospital, and actual time of leaving the hospital

Outcome Time Frame:

Up to 7 days or resolution

Safety Issue:


Principal Investigator

Marilyn J Telen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Duke University


United States: Food and Drug Administration

Study ID:




Start Date:

May 2010

Completion Date:

June 2013

Related Keywords:

  • Sickle Cell Disease
  • Vaso-occlusive Crisis
  • Pain Crisis
  • Sickle Cell Disease
  • Anemia, Sickle Cell



University of Mississippi Medical Center Jackson, Mississippi  39216-4505
New York Methodist Hospital Brooklyn, New York  11215-3609
Boston Medical Center Boston, Massachusetts  02118
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania  15213
University of Connecticut Health Center Farmington, Connecticut  06360-7106
University of Colorado Denver, Colorado  80217
Duke University Medical Center Durham, North Carolina  27710
University of California, Davis Medical Center Sacramento, California  
Virginia Commonwealth University Richmond, Virginia  
Karmanos Cancer Institute Detroit, Michigan  48201
The Children's Hospital of Philadelphia Philadelphia, Pennsylvania  19104
University Of Miami Miller School Of Medicine Miami, Florida  33010
Children's Hospital at Montefiore Bronx, New York  10467
UT Southwestern Medical Center at Dallas Dallas, Texas  75390
Alta Bates Summit Medical Center Berkeley, California  94704
Georgia Health Sciences University Augusta, Georgia  30912
University of Alabama Hospital Birmingham, Alabama  35294
The Johns Hopkins School of Medicine Baltimore, Maryland  21205
University of Illinois, Chicago Chicago, Illinois  60612
Cincinnati Childrens' Hospital Cincinnati, Ohio  45229